Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Challenges in initiating antiretroviral therapy in 2010.
Tremblay CL, Baril JG, Fletcher D, Kilby D, Macpherson P, Shafran SD, Tyndall MW. Tremblay CL, et al. Among authors: shafran sd. Can J Infect Dis Med Microbiol. 2010 Aug;21 Suppl C(Suppl C):1C-15C. Can J Infect Dis Med Microbiol. 2010. PMID: 23365594 Free PMC article.
Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.
Tan DHS, Hull MW, Yoong D, Tremblay C, O'Byrne P, Thomas R, Kille J, Baril JG, Cox J, Giguere P, Harris M, Hughes C, MacPherson P, O'Donnell S, Reimer J, Singh A, Barrett L, Bogoch I, Jollimore J, Lambert G, Lebouche B, Metz G, Rogers T, Shafran S; Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network. Tan DHS, et al. CMAJ. 2017 Nov 27;189(47):E1448-E1458. doi: 10.1503/cmaj.170494. CMAJ. 2017. PMID: 29180384 Free PMC article. No abstract available.
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
Loutfy MR, Ackad N, Antoniou T, Baril JG, Conway B, de Wet J, Trottier B, Kovacs CM, Thompson W, Martel AY, Trottier S, Rouleau D, Shafran SD, Rachlis A, Fraser C, Smaill F, Walmsley SL, Tseng AL, Sampalis JS. Loutfy MR, et al. Among authors: shafran sd. HIV Clin Trials. 2007 Sep-Oct;8(5):259-68. doi: 10.1310/hct0805-259. HIV Clin Trials. 2007. PMID: 17956827 Clinical Trial.
Pharmacology and clinical experience with amprenavir.
Conway B, Shafran SD. Conway B, et al. Among authors: shafran sd. Expert Opin Investig Drugs. 2000 Feb;9(2):371-82. doi: 10.1517/13543784.9.2.371. Expert Opin Investig Drugs. 2000. PMID: 11060683
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Fätkenheuer G, et al. N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154. N Engl J Med. 2008. PMID: 18832245 Free article.
162 results